SynthesisInfection2026
Efficacy and safety of Gepotidacin for urogenital infections: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGepotidacin is a novel triazaacenaphthylene antibiotic that has been proven to be an effective therapeutic option for several urogenital infections, including Neisseria gonorrhoeae (NG). Amidst the rising antimicrobial resistance, this offers a promising alternative to traditional antibiotics. This systematic review and meta-analysis evaluate its efficacy and safety in treating urogenital infections.
methodsA systematic search of PubMed, Embase and Scopus identified Randomized Controlled Trials (RCTs) comparing Gepotidacin with standard antibiotics for urogenital infections from inception up to May 24th, 2025. Data were analyzed using RevMan 5.4.1. Pooled risk ratios (RRs) with 95% CIs were calculated using Mantel-Haenszel methods. Fixed- or random-effects models were used based on heterogeneity (I
findingsThree RCTs (N = 3756) were included. Gepotidacin achieved similar microbiological cure rates for urogenital NG vs. controls (RR 1.10; 95% CI 0.96-1.27; p = 0.17; I
interpretationGepotidacin demonstrates comparable efficacy to standard antibiotic treatment options for Neisseria gonorrhoeae and other urogenital infections. However, it is associated with a significantly higher incidence of gastrointestinal adverse events and elevated liver enzymes, which may impact patient tolerability and compliance.
Indexed as
Identifiers
41931189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.